Home | Welcome to Contract Pharma   
Last Updated Monday, December 22 2014

Print

Breaking News

February 9, 2012
New Lab investment includes polymorph and salt screening and solid form development  Read More »
February 9, 2012
To provide oral product formulation and analytical services in SkyePharma facility  Read More »
February 9, 2012
Allows for preparation and compounding of compounds for early studies  Read More »
February 9, 2012
Will lead the medical and regulatory service groups  Read More »
February 8, 2012
Capabilities aim to provide more efficient trial execution  Read More »
February 8, 2012
Will continue to provide development support services  Read More »
February 8, 2012
Inhaled therapy panel to be on market in late 2012  Read More »
February 8, 2012
Tysabri sales were up 23% in 2011  Read More »
February 8, 2012
Genzyme revenues, growth offset generic impact on flagship products   Read More »
February 7, 2012
Vaccines sales drop 19% in 2011  Read More »
February 7, 2012
Expands early development capabilities  Read More »
February 7, 2012
Silva to focus on corporate strategy, acquisitions, outlicensing  Read More »
February 6, 2012
Senior analytical staff to relocate to Germantown, MD  Read More »
February 6, 2012
Biogen assumes full development responsibilities and costs  Read More »
February 6, 2012
Koven to serve as CAO and general counsel, and Glickman as SVP of sales  Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On